{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:26:45Z","timestamp":1791163605398,"version":"4.1.0"},"reference-count":24,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T00:00:00Z","timestamp":1211932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2008,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>B-cell expansion is a key feature of Sj\u00f6gren\u2019s syndrome (SS). Accordingly, several studies have reported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (Rituximab) in the treatment of glandular and extraglandular manifestations of SS. Patients with SS are at increased risk of lymphoma development. B-lymphocyte stimulator (BAFF) is an essential cytokine for the control of B-cell maturation and survival, and high levels of BAFF were described in the serum and salivary glands of SS patients, strongly suggesting a crucial role in the proliferation of B cells in SS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient and Methods<\/jats:title>\n                    <jats:p>We describe the treatments employed, with particular regards to rituximab therapy, and the histopathologic and biologic studies, in particular BAFF levels in serum and in pathologic tissues before and after B-cell depletion therapy, and the characterization of the cultured epithelial cells obtained by the parotid gland MALT-lymphoma, in a case of a 51-year old woman with primary SS and mixed cryoglobulinaemia type II with features of systemic vasculitis, who developed a bilateral parotid MALT-type lymphoma. Rheumatoid factor (RF), cryoglobulins, BAFF levels were assessed monthly up to month +6, then at the end of follow-up (month +12), as well as peripheral blood CD19-positive B-cell level<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A significant systemic effect of rituximab on B-cell biomarkers was documented, however, the cryoglobulinemic syndrome did not improve and the parotid enlargement did not decrease confirming the failure of B-cell depletion to affect the parotid lymphoma. BAFF levels decreased only under B-cell depletion associated with high-dose steroids. Tissue studies further documented the persistent overexpression of BAFF in the salivary gland pathologic tissue during the disease course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tissue and systemic overexpression of BAFF may have contributed to resistance to rituximab therapy, in MALT lymphoproliferation associated with SS. Thus, alternative treatment strategies should be then considered, possibly including BAFF-targeted approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1874312900802010038","type":"journal-article","created":{"date-parts":[[2008,6,3]],"date-time":"2008-06-03T13:18:45Z","timestamp":1212499125000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Resistance to Rituximab Therapy and Local BAFF Overexpression in Sj\u00f6gren\u2019s Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma"],"prefix":"10.2174","volume":"2","author":[{"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rupolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Beltrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","volume":"29","author":"Skopouli FN","year":"2000","unstructured":"Skopouli FN, Dafni U, Ioannidis JPA, Moutsopoulos HM. \n                    Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome \n                    Semin Arthritis Rheum  \n                    2000; \n                    29\n                    : 296-304.","journal-title":"Semin Arthritis Rheum"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","volume":"49","author":"Somer BG","year":"2003","unstructured":"Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. \n                    Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma \n                    Arthritis Rheum Arthritis Care Res  \n                    2003; \n                    49\n                    : 394-98.","journal-title":"Arthritis Rheum Arthritis Care Res"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.1533","volume":"202","author":"Lavie F","year":"2004","unstructured":"Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. \n                    Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sj\u00f6gren's syndrome \n                    J Pathol  \n                    2004; \n                    202\n                    : 496-502.","journal-title":"J Pathol"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"Mariette X","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, et al. \n                    The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome \n                    Ann Rheum Dis  \n                    2003; \n                    62\n                    : 168-71.","journal-title":"Ann Rheum Dis"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"Novak AJ","year":"2004","unstructured":"Novak AJ, Grote DM, Stenson M, et al. \n                    Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome \n                    Blood  \n                    2004; \n                    104\n                    : 2247-53.","journal-title":"Blood"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"Vitali C","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R. \n                    Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group \n                    Ann Rheum Dis  \n                    2002; \n                    61\n                    : 554-8.","journal-title":"Ann Rheum Dis"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1006\/bcmd.2001.0446","volume":"27","author":"De Vita S","year":"2001","unstructured":"De Vita S, De Marchi G, Sacco S, Gremese E, Fabris M, Ferraccioli G. \n                    Preliminary classification of nonmalignant B cell proliferation in Sj\u00f6gren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach \n                    Blood Cells Mol Dis  \n                    2001; \n                    27\n                    : 757-66.","journal-title":"Blood Cells Mol Dis"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1073\/pnas.91.19.9004","volume":"91","author":"Curcio F","year":"1994","unstructured":"Curcio F, Ambesi-Impiombato FS, Perrella G, Coon HG. \n                    Long-term culture and functional characterization of follicular cells from adult normal human thyroids \n                    Proc Natl Acad Sci USA  \n                    1994; \n                    91\n                    : 9004-8.","journal-title":"Proc Natl Acad Sci USA"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.22458","volume":"56","author":"Daridon C","year":"2007","unstructured":"Daridon C, Devauchelle V, Hutin P, et al. \n                    Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sj\u00f6gren's syndrome \n                    Arthritis Rheum  \n                    2007; \n                    56\n                    : 1134-44.","journal-title":"Arthritis Rheum"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar1912","volume":"8","author":"Ittah M","year":"2006","unstructured":"Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. \n                    B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome \n                    Arthritis Res Ther  \n                    2006; \n                    8\n                    : R51-00.","journal-title":"Arthritis Res Ther"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2004.030684","volume":"64","author":"Pijpe J","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Vissink A, et al. \n                    Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma \n                    Ann Rheum Dis  \n                    2005; \n                    64\n                    : 958-60.","journal-title":"Ann Rheum Dis"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/keh248","volume":"43","author":"Voulgarelis M","year":"2004","unstructured":"Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG. \n                    Combined therapy with rituximab plus cyclophosphamide\/doxorubicin\/ vincristine\/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non Hodgkin's lymphomas \n                    Rheumatology  \n                    2004; \n                    43\n                    : 1050-53.","journal-title":"Rheumatology"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/keh308","volume":"43","author":"Harner KC","year":"2004","unstructured":"Harner KC, Jackson LW, Drabick JJ. \n                    Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome \n                    Rheumatology  \n                    2004; \n                    43\n                    : 1309-0.","journal-title":"Rheumatology"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1191\/0961203304lu2049xx","volume":"13","author":"Ramos-Casals M","year":"2004","unstructured":"Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P, Cervera R, Font J. \n                    Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's sindrome associated with hepatitis C virus infection \n                    Lupus  \n                    2004; \n                    13\n                    : 969-71.","journal-title":"Lupus"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"Gottenberg JE","year":"2005","unstructured":"Gottenberg JE, Guillevin L, Lambotte O, et al. \n                    Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases \n                    Ann Rheum Dis  \n                    2005; \n                    64\n                    : 913-20.","journal-title":"Ann Rheum Dis"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.2005.046193","volume":"65","author":"Voulgarelis M","year":"2006","unstructured":"Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. \n                    Long-term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide\/doxorubicin\/vin-cristine\/prednisone) \n                    Ann Rheum Dis  \n                    2006; \n                    65\n                    : 1033-37.","journal-title":"Ann Rheum Dis"},{"key":"refR17","first-page":"891","volume":"25","author":"Pijpe J","year":"2006","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK, et al. \n                    Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study \n                    Arthritis Rheum  \n                    2006; \n                    25\n                    : 891-94.","journal-title":"Arthritis Rheum"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"Seror R","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, et al. \n                    Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome \n                    Ann Rheum Dis  \n                    2007; \n                    66\n                    : 351-57.","journal-title":"Ann Rheum Dis"},{"key":"refR19","unstructured":"De Vita S, De Marchi G, Sacco S, Zaja F, Scott CA, Ferraccioli G. \n                    Treatment of B-cell disorders of MALT in Sj\u00f6gren's syndrome with anti-CD20 monoclonal antibody \n                    \n                     In: The VIIIth international symposium on Sjgren's syndrome; \n                    Kanazawa, Japan. 2002."},{"key":"refR20","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","volume":"48","author":"Stohl W","year":"2003","unstructured":"Stohl W, Metyas S, Tan S-M. \n                    B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus \n                    Arthritis Rheum  \n                    2003; \n                    48\n                    : 3475-86.","journal-title":"Arthritis Rheum"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","volume":"54","author":"Cambridge G","year":"2006","unstructured":"Cambridge G, Stohl W, Leandro MJ, Magone TS, Hilbert DM, Edwards JC. \n                    Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse \n                    Arthritis Rheum  \n                    2006; \n                    54\n                    : 723-32.","journal-title":"Arthritis Rheum"},{"key":"refR22","first-page":"1674","volume":"22","author":"De Vita S","year":"1995","unstructured":"De Vita S, Dolcetti R, Ferraccioli G, et al. \n                    Local cytokine expression in the progression toward B cell malignancy in Sjogren's syndrome \n                    J Rheumatol  \n                    1995; \n                    22\n                    : 1674-80.","journal-title":"J Rheumatol"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Gong Q","year":"2005","unstructured":"Gong Q, Ou Q, Ye S, et al. \n                    Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy \n                    J Immunol  \n                    2005; \n                    174\n                    : 817-26.","journal-title":"J Immunol"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","volume":"56","author":"Pers JO","year":"2007","unstructured":"Pers JO, Devauchelle V, Daridon C, et al. \n                    BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sj\u00f6gren's syndrome \n                    Arthritis Rheum  \n                    2007; \n                    56\n                    : 1464-77.","journal-title":"Arthritis Rheum"}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V2\/TORJ-2-38\/TORJ-2-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V2\/TORJ-2-38\/TORJ-2-38.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V2\/TORJ-2-38\/TORJ-2-38.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:00:35Z","timestamp":1761548435000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/2\/PAGE\/38\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,28]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,5,28]]}},"alternative-id":["TORJ-2-38"],"URL":"https:\/\/doi.org\/10.2174\/1874312900802010038","relation":{},"ISSN":["1874-3129"],"issn-type":[{"value":"1874-3129","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2008-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-01-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}